Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00330044 · ClinicalTrials.gov registry record · Phase 1
Alimta, Carboplatin and Radiation Therapy for Non Small Cell Lung Cancer
A Phase 1 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT00330044 is a Phase 1 study that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University. The registered enrollment target is 18 participants.
The verdict
NCT00330044, a Phase 1 study, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
To determine the safety of Alimta when used with chemoradiation in inoperable non small cell lung cancer
Interventions
- DRUG Carboplatin
- DRUG Premetrexed (Alimta)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2006-04 |
| Est. Completion | 2009-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00330044
The ClinicalTrials.gov registry entry for NCT00330044 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University, which has 138 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Carboplatin is the first listed.
NCT00330044 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00330044 about?
NCT00330044 is a clinical study titled "Alimta, Carboplatin and Radiation Therapy for Non Small Cell Lung Cancer". To determine the safety of Alimta when used with chemoradiation in inoperable non small cell lung cancer
What is the current status of trial NCT00330044?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2006-04. Estimated completion is 2009-10.
What interventions are being tested in trial NCT00330044?
The interventions under investigation include: Carboplatin (DRUG), Premetrexed (Alimta) (DRUG).
Who is sponsoring clinical trial NCT00330044?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University, which has 138 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.